Could a single injection replace biopsies for breast cancer?
NCT ID NCT05695859
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new imaging method that uses a radioactive tracer to detect HER2 protein in breast cancer tumors and nearby lymph nodes. 24 women with primary breast cancer received one injection followed by a scan. The goal was to see if the scan results matched standard tissue tests. If it works, this could offer a less invasive way to check HER2 status.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Technetium-99m-labelled DARPinG3
- What this could lead to
- If successful, this imaging method could help doctors see HER2 levels in breast cancer tumors without needing a biopsy, making diagnosis faster and less invasive.
- What could go wrong
- This is a small, early study with only 24 participants, so results may not apply to everyone. The imaging accuracy needs to be confirmed in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Russia Tomsk NRMC
Tomsk, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?